EMQN is pleased to announce that it has been shortlisted for the Quality Assurance and Control Award at the Pharma Industry Awards for its entry, External Quality Assessment in Genomics.
The shortlisting recognises EMQN’s ongoing commitment to supporting quality, accuracy and confidence in genetic and genomic testing through its international External Quality Assessment (EQA) programmes. These programmes enable laboratories to benchmark performance, drive continuous improvement and maintain the highest standards in diagnostic testing.
EMQN is honoured to be recognised alongside fellow finalists AstraZeneca, Ipsen Biopharm Ltd and Upperton Pharma Solutions, reflecting the importance of quality assurance and control across the pharmaceutical, biotechnology and healthcare sectors.
The Pharma Industry Awards celebrate excellence, innovation and achievement across the life sciences industry. The Quality Assurance and Control Award recognises organisations that demonstrate a strong commitment to quality systems, operational excellence and continuous improvement.
This recognition highlights the critical role of external quality assessment in supporting reliable genomic testing and helping laboratories deliver accurate results that inform patient care and clinical decision-making.
As a trusted provider of EQA services to laboratories worldwide, EMQN remains committed to advancing quality standards across the genomics community and supporting best practice throughout an evolving healthcare landscape.
The winners will be announced at the Pharma Industry Awards ceremony later this year.
